Podcasts about oculeve

John Chuback, M.D., Monika Gloviczki, M.D., Emily Iker, M.D., and Mark Melin, M.D. On today's Episode #23, Dr. Chuback, Dr. Iker, Dr. Gloviczki, and Dr. Melin welcomed ANDY DORAISWAMY, a Health Care and Human Life Scientist. FROM HIS LINKED BIO: Andy is focused on advancing health and human life. He enjoys bringing bold and innovative teams together to ideate and improve health. He is the founder and CEO of Koya Medical, a team dedicated to transforming venous and lymphatic disease. He also serves as Chairman and board director with an eye-care and urology health venture.  Previously, he led Oculeve, a first-in-class health venture backed by NEA, Kleiner Perkins, and Versant to treat ocular disorders with a revolutionary neuromodulation platform. The company was acquired by Allergan Plc. Prior to this, Andy invented sight-restoring intraocular implants that have given sight to more than 6 million humans across the globe. This technology was acquired by Santen Pharmaceuticals and licensed to Bausch & Lomb (marketed as envista IOL).  He is trained as a scientist with a specialization in biomedical applications to solve diseases and extend healthy human life. 

Julia Child was a master. She was not a classically trained chef, but pursued cooking as a hobby. Her super power? Passion. A passion for making gastronomy accessible, to deliver an honest and attainable presentation, and she possessed a pure, unadulterated joy for her craft. While https://www.linkedin.com/in/michaelackermann/ (Michael Ackermann) isn't a neurotechnolgy hobbyist, he does share other qualities with the inimitable Child. He brings a passion for neurotechnology, mixes it with technical expertise picked up at https://engineering.case.edu/ebme/ (Case Western Reserve University), panache earned through his time at Stanford BioDesign, and pairs it with an excellent vintage of management style.  Hungry yet? We thought you might be. Ackermann was actually one of our early targets for an interview on Skraps. Perhaps it was his humility and desire to keep the focus on the science instead of the personalities that caused him to decline our first plea invitation to record with us, but maybe as we grew in our professionalism and track record, Michael became just a tiny bit more comfortable with the idea. But he did it. We did it. We finally got him on the podcast. I promise, it's worth the wait.  Listen on for the behind the science peek at Ackermann's time in the BioDesign Program, check in as he deftly maneuvers Oculeve to success, and check out what's happening now at Presidio Medical and beyond. Who knows what's next? Perhaps a chocolate soufflé for his wife's recent birthday (I know this because he was unable to join the Cleveland NeuroDesign faculty in person.) Bon appétit! Papers of interest: https://pubmed.ncbi.nlm.nih.gov/34433642/ (Presidio's published research ) Michael Ackermann's https://patents.google.com/?inventor=Michael+Ackermann (Patents on Nerve Block) SKRAPS is your podcast, where we on your behalf explores unsaid, underappreciated and sometimes, untold stories of sparks of brilliance in science, technology and innovation. Show Credits Created & Produced by: https://www.linkedin.com/in/arun11sridhar/ (Arun Sridhar) & https://www.linkedin.com/in/jojoplatt/ (JoJo Platt) Editing: Arun Sridhar Sound design: Arun Sridhar & Swaminathan ThiruGnanaSambandam Sound mixing and mastering: Swaminathan ThiruGnanaSambandam Social Media: Twitter: https://twitter.com/PodcastSkraps (@PodcastSkraps) LinkedIn: https://www.linkedin.com/company/skrapspodcast (SKRAPS) https://twitter.com/skrappyscience (Arun's Twitter Feed) https://twitter.com/RockinRedSF (JoJo's Twitter Feed) You can help us fund the production costs by donating as little as $5 or £5 or in any currency of your choice as a one time or a recurring payment HERE

Before he began his Ph.D. program in biomedical engineering, Andy Doraiswamy bought a one-way ticket to Southeast Asia to explore and “find himself.” He was successful: discovering a love for mountain climbing's physical and mental challenges and developing a practice of meditation that has proven helpful in both climbing and commerce. Since leaving academia, he's been involved in startups at Advanced Vision Science, Oculeve, and now Koya Medical. Doraiswamy has a huge bias and love for eye care, he says, particularly intrigued by its complexity. He and host Geoff Pardo discuss how medical devices fare in academia, letting go of promising technology in an acquisition, and the shifts required when transitioning from COO to CEO. Links from this episode: Koya Medical 

Dr Daniel Palanker is Professor of Opthamology at Stanford University. He has had many successful technologies spun off into companies or patents including those involving retinal prosthetics, optical imaging and spectroscopy, laser-tissue interactions, and retinal plasticity. Top 3 Takeaways "The [size] limitation for a retinal prosthesis is not in a fabrication side. The limitation is an interface with neurons" Allergan acquired Oculeve but then didn't do much with it seemingly because they already had a more profitable drug on the market "Stanford is industry-friendly, encouraging commercialization, basically making things practical and useful and in Berkeley it's a communist mentality" 1:15 "You've worked on a railroad. Do you want to talk about this a little bit?" 2:00 "I introduced you a little bit, but do you want to describe yourself and your role?" 3:00 "The retinal prosthesis is a very fascinating technology. What's the advantage of this versus something else?" 7:15 "Tell me about the progress of this technology. Where did it start and how far has it progressed in the many years since you've been working on it" 14:00 "It seems there's a curse, on these vision prosthetics companies and the SecondSight and actually Pixium also has stuttered a little bit in the last year or so. Do you want to comment?" 19:30 "You mentioned this sub 40 micron photo detector, do you see a potential for, getting down to the five and the three micron size of that you had mentioned?" 22:45 "Did you want to talk about TrueTear and Oculeve a little bit?" 24:00 "If you suspect [a company buying your tech and shelving it] were to happen the then would you would you go through with that sale or would you continue to develop it yourself?" 25:15 "I was reading you have 70 patents and seven platform technologies... Is this a Stanford thing? Do you have access to great talent or are the projects you're working on especially good at spinning off these companies?" 27:15 "Is there anything else that you're excited about? Any other crazy physics rules that you're gonna be breaking?" 33:00 "Is there anything that we didn't talk about that you wanted to mention?"  

Oyster Point Pharma CEO Jeff Nau sheds some light on the new dry eye start-up, which is tapping much of the leadership and investment team that made Oculeve successful. He also talks about his own experiences leading high-profile clinical programs at Ophthotech and Genentech. What lessons will he bring into his new CEO role?

After capturing lighting in a bottle with Oculeve, Ali Behbahani, MD, partner of New Enterprise Associates, recalls the experience with the Dry Eye start-up and lays out his plans for investing in future ophthalmology start-ups.

From his clinic in South Dakota, Vance Thompson has served as an investigator in over 60 clinical trials. Thompson taps this experience to shed some light on new innovations being brought forth by Zeiss, Avedro, Allergan, and RxSight. He also offers a few insights on new advances coming down the pike.

Oculeve’s stunning acquisition by Allergan last week led us back to a conversation we had with Mark S. Blumenkranz, MD, Professor & Chairman of the Department of Ophthalmology, Stan-ford University. Mark S. Blumenkranz is the H.J. Smead Professor and Chairman of the De-partment of Ophthalmology at Stanford University. He received his Baccalaureate, Master of Medical Science, and MD degrees at Brown University, followed by a Residency in Ophthalmol-ogy at Stanford. Dr. Blumenkranz is a noted vitreoretinal surgeon who served as Co-Director of the Retinal Service at Stanford for five years prior to assuming the Chairmanship in November 1997.

Oculeve, a stealthy start-up with backing from Kleiner, NEA and Versant, opted to sell its neurostim treatment for Dry Eye to Ophthalmology Leader Allergan.

Oculeve CEO Michael Ackermann Talks About Allergan’s Big Move in Dry Eye. The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Learn more about: Sponsorship Presenting Companies Any other questions? Contact the producer of OIS, Craig Simak.